Last reviewed · How we verify
RIAMET (artemether + LUMEFANTRIN combination)
Riamet combines artemether, a fast-acting antimalarial, with lumefantrine, a longer-acting partner, to provide a synergistic effect against Plasmodium falciparum.
Riamet is a fixed-dose combination of artemether and lumefantrine, developed by Assistance Publique - Hôpitaux de Paris for the treatment of uncomplicated malaria caused by Plasmodium falciparum. The drug works by targeting the parasite's ability to replicate and survive within red blood cells. Riamet is not approved by the FDA but is widely used in regions where malaria is endemic. It is generally well-tolerated, but common side effects include headache, dizziness, and gastrointestinal disturbances. The drug is contraindicated in patients with known hypersensitivity to artemether, lumefantrine, or any of the excipients.
At a glance
| Generic name | RIAMET (artemether + LUMEFANTRIN combination) |
|---|---|
| Also known as | artemether+LUMEFANTRIN combination |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Antimalarial |
| Target | Plasmodium falciparum |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Mechanism of action
Artemether rapidly reduces the parasite biomass by disrupting its metabolic pathways, while lumefantrine prolongs the therapeutic effect, preventing recrudescence.
Approved indications
Common side effects
- Headache
- Dizziness
- Nausea
- Vomiting
- Diarrhea
- Loss of appetite
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: